AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01775826 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurement
Description: Measured usual (day-to-day) behavior with body-worn sensors.
Study NCT01898039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DNP sensititzation
Description: Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.
Study NCT01898039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
Study NCT04473248 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spartan COVID-19 System
Description: PCR analysis of patient samples using the Spartan COVID-19 System
Study NCT04070261 — intervention group
Intervention type: OTHER
Intervention: iOS application usability test
Description: user tasks, questionnaires, semi-structured interviews
Study NCT04043039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal wound bandage with PRF
Description: palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
Study NCT04043039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal wound bandage with PRF
Description: palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
Study NCT04043039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal wound bandage with Gelatine Sponge
Description: palatal wound will be protected by gelatine sponge
Study NCT04043039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Palatal wound bandage with Gelatine Sponge
Description: palatal wound will be protected by gelatine sponge
Study NCT04159246 — intervention group
Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~* Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~* The patient will be examined before and after finishing the treatment course
Study NCT04159246 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir (Sovaldi)
Description: Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
Study NCT02038257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MKTP (melanocyte keratinocyte transplant procedure)
Description: Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
Study NCT02038257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Dressing
Description: Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
Study NCT01683825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 florbetapir PET
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
Study NCT01683825 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F-18 florbetapir PET
Description: Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
Study NCT01528189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinemic normoglycemic clamp
Description: Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
Study NCT01528189 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard glucose management
Description: Blood glucose levels will be treated by a standard insulin sliding scale.
Study NCT04116073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012 (PD-1 antibody)
Description: 1. Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~2. Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)
Study NCT01122693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eZono - high-quality 2D ultrasound images
Description: higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
Study NCT01122693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eZono - high-quality 2D ultrasound images
Description: higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
Study NCT01122693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard 2D ultrasound images
Description: current standard in two-dimensional (2D) ultrasound images
Study NCT01122693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 2D ultrasound images
Description: current standard in two-dimensional (2D) ultrasound images
Study NCT00550966 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducative program in fibromyalgic patients
Description: Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
Study NCT02596789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TMS Magpro®, Magventure Inc device
Study NCT02805855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived Mesenchymal Stromal Cells
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
Study NCT00887926 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-EB10
Description: Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
Study NCT01561742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline will be given orally at 200 mg a day for 4 months
Study NCT01561742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: EquivalentPlacebo will be given
Study NCT02461940 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Behavioral Intervention
Description: Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
Study NCT03370224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study NCT03370224 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study NCT00771771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early supported discharge with day unit rehabilitation
Description: Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
Study NCT00771771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early supported discharge with home rehabilitation
Description: Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
Study NCT01444846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Low dose
Description: Oral capsules, 200 mg ebselen, twice daily, 4 days
Study NCT01444846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 Middle dose
Description: Oral capsules, 400 mg ebselen, twice daily, 4 days
Study NCT03596645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
Study NCT03596645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
Study NCT02816853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Domperidone 10 mg or 20 mg tablets will be administered.
Study NCT01444846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPI-1005 High dose
Description: Oral capsules, 600 mg ebselen, twice daily, 4 days
Study NCT01444846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules, 0 mg ebselen, twice daily, 4 days
Study NCT03629353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
Study NCT03629353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
Study NCT02663830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil & clomiphene citrate
Description: 105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Study NCT02663830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene only
Description: 105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
Study NCT03746717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusive wound closure
Description: skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
Study NCT03746717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional wound closure
Description: wound closure with surgical staples
Study NCT01625000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 3mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for six weeks.
Study NCT02816853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT01625000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 6mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for six weeks.
Study NCT01625000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-214 9mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for six weeks.
Study NCT01625000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone 4mg
Description: Patients who meet eligibility criteria will be administered a once daily oral 4mg of risperidone for six weeks.
Study NCT01625000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
Study NCT03078855 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: vitamin D3 2,000 IU daily
Study NCT03078855 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Administered weekly x 4
Study NCT03078855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered weekly x 4
Study NCT03078855 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: methylcellulose
Study NCT00147121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab + Standard CHOP
Description: Rituximab + Standard CHOP
Study NCT00147121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab + Bi-weekly CHOP
Description: Rituximab + Bi-weekly CHOP
Study NCT02816853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg tablet will be administered.
Study NCT02118493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Benign Biliary Stenosis, Laser
Description: Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
Study NCT02033642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Intervention
Description: Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child by monitoring diet and physical activity behaviors, setting goals, providing support and reinforcement, and assessing and making changes to the home environment.
Study NCT02033642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports, and prevent and manage relapse.
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: PARP-inihibitor
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: PD-1 inihibitor
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Chemotherapy drug
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy drug
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy drug
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Chemotherapy drug
Study NCT04679064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Chemotherapy drug
Study NCT00584428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Dose Chemo with Autologous BMT
Description: Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
Study NCT01411059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga classes 2 times per week for 32 weeks
Study NCT02141360 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study NCT02141360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Diagnostic
Description: Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
Study NCT04396158 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioactive iodine
Description: 80-200 mCi of radioactive iodine will be given to thyroid cancer patients
Study NCT04456192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Indoor Cycling Interval Exercise Training
Description: The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax.
Study NCT04456192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indoor Cycling Interval Exercise Training
Description: The 3-month intervention consisted of a physical exercise program involving three indoor cycling sessions per week, with a total of 36 training sessions. Subjects exercised on cycle ergometers Schwinn® Evolution® (Schwinn Bicycle Company, Boulder, Colorado, USA). Each session lasted approximately 55 minutes. Training sessions consisted of a 5-min low-intensity warm-up (cycling at 50-65% of maximum heart rate (HRmax)), 40 min of main training at an intensity of 65-95% of HRmax, 5 min of non-weight-bearing cycling, finishing with 5 min of low-intensity cool-down stretching and breathing exercises.~Main part of the training was interval. Each exercise session consisted of 3 to 4 high intensity intervals with intensity exceeding 80% of HRmax, often reaching anaerobic threshold. High intensity intervals lasted approximately 4-minutes and were interspersed by recovery periods at 65-80% of HRmax.
Study NCT02293603 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cardiosphere-Derived Cells (CDCs)
Description: Intracoronary delivery of CAP-1002 or placebo
Study NCT02293603 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic Cardiosphere-Derived Cells (CDCs)
Description: Intracoronary delivery of CAP-1002 or placebo
Study NCT01078389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat capsules
Study NCT01078389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Febuxostat
Description: Febuxostat placebo-matching capsules
Study NCT01873027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI
Description: * OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI
Study NCT01873027 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS
Description: * IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~* Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI
Study NCT03688464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.